Fibrin Modulating Agents

Fibrin Modulating Agents
Accession Number

Agents that affect the function of FIBRIN in BLOOD COAGULATION. They are used as COAGULANTS for HEMORRHAGE or ANTICOAGULANTS for THROMBOSIS.

DrugDrug Description
LepirudinA protein-based direct thrombin inhibitor used to reverse and prevent thrombus formation in heparin-induced thrombocytopenia.
AlteplaseA recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
ReteplaseA purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
AnistreplaseA form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
TenecteplaseA modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
StreptokinaseA purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism.
TiclopidineA platelet aggregation inhibitor used in the prevention of conditions associated with thrombi, such as stroke and transient ischemic attacks (TIA).
Tranexamic acidAn antifibrinolytic used to reduce or prevent hemorrhagic episodes, especially in the context of hyperfibrinolytic disorders.
ArdeparinFor prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.
Aminocaproic acidAn antifibrinolytic agent used to induce clotting postoperatively.
TirofibanA platelet aggregation inhibitor used to prevent thrombotic events in non-ST elevated acute coronary syndrome.
PhylloquinoneA fat soluble vitamin used to treat hemorrhagic conditions in infants and coumarin overdoses.
HeparinAn anticoagulant indicated for thromboprophylaxis and to treat thrombosis associated with a variety of conditions such as pulmonary embolism and atrial fibrillation.
EnoxaparinA low molecular weight heparin used for the prophylaxis of deep vein thrombosis and ischemic complications of unstable angina and non-Q-wave myocardial infarction.
DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
DefibrotideA mixture of single-stranded oligonucleotides used in the treatment of severe hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation.
AncrodAn anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country.
FibrinolysinFibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
SulodexideA drug used to treat chronic venous ulcers in the legs.
DanaparoidA heparinoid with anticoagulant and antithrombotic activities used for the treatment of acute episode of Heparin-Induced Thrombocytopenia (HIT), and for prophylaxis in patients with a history of HIT.
TinzaparinA low molecular weight heparin used for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin.
NadroparinA low molecular weight heparin used for the prophylaxis of thrombotic events and deep vein thrombosis, and prevent unstable angina and non-Q-wave myocardial infarction.
BatroxobinNo approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously.
DesirudinIndicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.
Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
OzagrelOzagrel has been used in trials studying the treatment of Dry Eye Syndromes.
SarpogrelateSarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.
NitroaspirinNitroaspirin has been investigated for the treatment of Intermittent Claudication.
HigenamineHigenamine is under investigation in clinical trial NCT01451229 (Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects).
BrinaseNot Annotated
SaruplaseNot Annotated
FondaparinuxAn anticoagulant used to prevent venous thromboembolism, to treat deep vein thrombosis, and to improve survival following myocardial infarction.
MonteplaseMonteplase has been used in trials studying the treatment of Pulmonary Embolism.
PlasminogenPlasma-derived human plasminogen administered intravenously to treat type 1 plasminogen deficiency (hypoplasminogenemia).
Drugs & Drug Targets
AlteplaseUrokinase plasminogen activator surface receptortarget
AlteplaseFibrinogen alpha chaintarget
AlteplasePlasminogen activator inhibitor 1target
ReteplaseFibrinogen alpha chaintarget
ReteplasePlasminogen activator inhibitor 1target
AnistreplaseFibrinogen alpha chaintarget
AnistreplasePlasminogen activator inhibitor 1target
TenecteplaseUrokinase plasminogen activator surface receptortarget
TenecteplasePlasminogen activator inhibitor 1target
TenecteplaseFibrinogen alpha chaintarget
TenecteplasePlasminogen activator inhibitor 2target
TenecteplaseKeratin, type II cytoskeletal 8target
TenecteplaseAnnexin A2target
TenecteplaseProlow-density lipoprotein receptor-related protein 1target
StreptokinaseProteinase-activated receptor 1target
StreptokinaseCytosolic phospholipase A2enzyme
TiclopidineP2Y purinoceptor 12target
TiclopidineCytochrome P450 2C19enzyme
TiclopidineCytochrome P450 2B6enzyme
TiclopidineCytochrome P450 2C9enzyme
TiclopidineCytochrome P450 2D6enzyme
TiclopidineCytochrome P450 1A2enzyme
TiclopidineCytochrome P450 2C8enzyme
TiclopidineCytochrome P450 2E1enzyme
Tranexamic acidPlasminogentarget
ArdeparinHeparin cofactor 2target
Aminocaproic acidPlasminogentarget
Aminocaproic acidTissue-type plasminogen activatortarget
Aminocaproic acidApolipoprotein(a)target
Aminocaproic acidAldehyde oxidaseenzyme
TirofibanIntegrin alpha-IIbtarget
TirofibanIntegrin beta-3target
PhylloquinoneVitamin K-dependent gamma-carboxylasetarget
PhylloquinoneLeukotriene-B(4) omega-hydroxylase 1enzyme
PhylloquinoneUbiA prenyltransferase domain-containing protein 1enzyme
PhylloquinoneVitamin K epoxide reductase complex subunit 1enzyme
HeparinCoagulation factor Xtarget
HeparinFibroblast growth factor receptor 4target
HeparinFibroblast growth factor 4target
HeparinFibroblast growth factor 19target
HeparinFibroblast growth factor receptor 1target
HeparinFibroblast growth factor 1target
HeparinFibroblast growth factor receptor 2target
HeparinFibroblast growth factor 2target
HeparinPlatelet factor 4target
HeparinHepatocyte growth factortarget
HeparinThyroxine-binding globulincarrier
EnoxaparinCoagulation factor Xtarget
DefibrotideAdenosine receptor A1target
DefibrotideAdenosine receptor A2atarget
DefibrotideAdenosine receptor A2btarget
AncrodFibrinogen alpha chaintarget
FibrinolysinPlasminogen activator inhibitor 1target
FibrinolysinUrokinase-type plasminogen activatortarget
SulodexideHeparin cofactor 2target
TinzaparinA disintegrin and metalloproteinase with thrombospondin motifs 4enzyme
TinzaparinIntegrin alpha-4target
TinzaparinStromal cell-derived factor 1target
NadroparinProto-oncogene c-Fostarget
NadroparinMyc proto-oncogene proteintarget
DesirudinCarboxypeptidase A1enzyme
Protein CCoagulation factor Vtarget
Protein CCoagulation factor VIIItarget
Sarpogrelate5-hydroxytryptamine receptor 2Ctarget
Sarpogrelate5-hydroxytryptamine receptor 2Atarget
NitroaspirinProstaglandin G/H synthase 1target
FondaparinuxCoagulation factor Xtarget
PlasminogenTissue-type plasminogen activatorenzyme
PlasminogenUrokinase-type plasminogen activatorenzyme